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Influence of specific nutrients on progression of atherosclerosis, vascular
function, haemostasis and inflammation in coronary heart disease
patients: a systematic review
Mark Hamer* and Andrew Steptoe
Department of Epidemiology and Public Health, University College London, 1–19 Torrington Place, London, WC1E 6BT, UK
(Received 1 July 2005 – Revised 12 January 2006 – Accepted 12 January 2006)
Epidemiological evidence suggests that the diet influences CHD risk, although the protective effects of dietary intervention for patients in diseased
states has gained less attention. Secondary care prevention strategies for patients often involves drug therapy that is expensive and can result in
undesirable side effects. Therefore, it is potentially beneficial to utilise other strategies, such as diet, in the management of CHD. A systematic
review was conducted to examine the effects of specific nutrients on progression of atherosclerosis, vascular function, haemostasis and inflam-
mation in CHD patients. Results show substantial evidence for the efficacy of n-3 oils in reducing cardiovascular mortality and one mechanism
may be related to the stabilisation of vulnerable atherosclerotic plaques, although the effects on progression of atherosclerosis, haemostatic activity
and vascular inflammation remain equivocal. Promising data also exist for the efficacy of flavonoid-rich foods for improving endothelial function,
although strong clinical endpoint evidence is lacking. The variation in the efficacy of certain nutrients in CHD patients may be explained by gen-
etics, existing risk factors, psychosocial factors and methodological issues, although these are often not adequately taken into consideration. We
conclude that there is a need to undertake more appropriately designed trials in specific clinical populations, controlling for additional lifestyle and
risk factors, examining potential interactions with medications, and also establishing methods to increase compliance to dietary recommendations
before specific nutrients can be widely prescribed for secondary prevention. Future research should also utilise techniques that provide a direct
measure of atherosclerosis.
Coronary heart disease management: Fish oils: Flavonoids: Endothelial function: Inflammation
It is well accepted that lifestyle factors, particularly diet,
account for a substantial proportion of the variation in CHD
risk. Thus, there is a growing worldwide interest in the pro-
spect that food and food products can promote and maintain
good health. In the past, health-focused dietary approaches
have included reducing the level of salt, refined sugar and
saturated fats in the diet. However, in recent years more atten-
tion has focused on promoting the consumption of specific
nutrients that are present in natural food sources, which is
the topic of the present review. This approach has gained sup-
port because the public in general appears to be more likely to
consume nutritious food, rather than restrict themselves from
something they like. In particular, the beneficial effects of
dietary nutrients on cardiovascular health have been exten-
sively explored and continue to receive considerable attention
in the scientific literature. The flavonoids, which are present in
high amounts in apples, onions, red wine, cocoa, red fruits,
citrus fruits and tea, have undoubtedly received the most
attention in relation to cardiovascular risk and data from
numerous epidemiological studies generally show that a
higher flavonoid intake is associated with lower CVD risk
(for reviews, see Vita, 2003, 2005). Dietary sources rich in
n-3 fatty acids, such as fish (containing EPA and DHA) and
certain nuts and plants (containing a-linolenic acid), have
also gained considerable attention with recent backing from
the US Food and Drug Administration that has approved a
heart health claim for n-3 fatty acids in foods and sup-
plements. This claim is based on extensive evidence docu-
menting the cardiovascular health benefits of n-3 fatty acid
intake. For example, in a recent meta-analysis of fourteen
cohort and five case–control-led studies, fish consumption v.
no or little fish consumption was associated with a 20%
reduction in the relative risk of fatal and a 10% reduction in
non-fatal CHD (Whelton et al. 2004). Also, much attention
has focused on the cardioprotective effects of the Mediterra-
nean diet, which is characterised by a high content of
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a-linolenic acid, phytochemicals and antioxidants (Robertson
& Smaha, 2001). This interest has largely stemmed from the
results of the Seven Countries Study that showed the mortality
rate from CHD was two- to threefold lower in Southern
Europe than in Northern Europe and America (Renaud et al.
1995), which was associated with the Mediterranean diet.
Further prospective data have demonstrated cardiovascular
health benefits for fruit and vegetable consumption
(Joshipura et al. 2001; Liu et al. 2001).
In contrast, the cardiovascular health benefits of specific
nutrients for CHD patients have gained less attention. In
CHD patients the secondary prevention care strategies often
involve drug therapy that is expensive and often results in
undesirable side effects. Therefore, it is potentially beneficial
to utilise other strategies, such as diet therapy, in the manage-
ment of various CVD states. Given the complex physiology of
CHD patients, it is important to test the efficacy of dietary
interventions in patient populations and not draw on con-
clusions from studies with otherwise healthy participants.
We therefore performed a systematic search in the MEDLINE
database for literature that has examined the effect of specific
nutrients on mortality, progression of atherosclerosis, vascular
function, haemostasis, and inflammation in patients with
established CHD. All relevant English-language articles pub-
lished between 1980 and 2005 in the MEDLINE database
were searched using the MeSH search terms ‘coronary dis-
ease’, ‘inflammation’, ‘haemostasis’, ‘cardiovascular
system’, with the terms ‘diet therapy’, ‘flavonoids’, ‘tea’,
‘alcohol’ or ‘fish oils’. The search was further limited to ran-
domised controlled trials (RCT) and prospective cohort
studies. Using these search terms a total of 325 papers were
retrieved. After review of the retrieved papers for studies con-
taining patients with established CHD, fifty-two papers were
included in the present review (Table 1). The effects of vita-
mins and L-arginine on risk markers in CHD have been pre-
viously reviewed (Hornig, 2002; Preli et al. 2002; Doshi
et al. 2003; Moat et al. 2004) and therefore only recent clini-
cal outcome trials were included in the present review. Also,
given that the aim of present review was to focus on the con-
sumption of specific nutrients, interventions that involved diet-
ary restriction (i.e. reducing energy intake, saturated fats, salt
and sugar) were also excluded.
Effects of diet on risk of mortality in coronary patients
Aprospective cohort study in theUSA showed that self-reported
moderate and heavy tea consumption in the year before acute
myocardial infarction (AMI) was associated with lower mor-
tality after infarction (Mukamal et al. 2002). In a prospective
cohort study that examined nearly half a million US adults,
and recorded deaths occurring in the subsequent 9 years, there
was an L-shaped association between alcohol consumption
and mortality from CHD in participants with pre-existing
CVD (Thun et al. 1997). Thus non-drinkers recorded the greatest
risk. Several studies have also shown that self-reported low to
moderate alcohol consumption is associated with reduced mor-
tality and risk of cardiovascular complications following AMI
(Muntwyler et al. 1998; Mukamal et al. 2001; de Lorgeril et al.
2002) and in patients with left ventricular dysfunction (Cooper
et al. 2000). However, other studies have shown alcohol intake
at baseline or following AMI did not alter the risk for the
development of symptomatic heart failure (Aguilar et al.
2004) and compared with occasional drinking, regular light
alcohol consumption in men with established CHD was not
associated with any benefit or deleterious effects (Shaper &
Wannamethee, 2000). Collectively, these studies tend to suggest
that the constituents of alcohol and tea may be associated with
increased survival of patients, although given that most studies
examined dietary intake before myocardial infarction, it is diffi-
cult to assess whether changes in intake following myocardial
infarction had any significant impact. A further methodological
issue relates to the fact that most studies measure average con-
sumption and not drinking patterns; thus, in the case of alcohol,
binge drinking may not be protective (Bobak &Marmot, 2005).
Indeed, binge drinking among AMI patients has recently been
associated with a two fold higher mortality rate (Mukamal
et al. 2005). Furthermore, dietary intake may be significantly
Table 1. Studies identified in the systematic review
Reference
Aguilar et al. (2004)
Angerer et al. (2002)
Barzi et al. (2003)
Berstad et al. (2003)
Bucher et al. (2002)*
Burr et al. (1989)
Burr et al. (2003)
Chou et al. (2001)
Cooper et al. (2000)
de Lorgeril et al. (1999)
de Lorgeril et al. (2002)
Duffy et al. (2001a)
Duffy et al. (2001b)
Eritsland et al. (1995)
Erkkila et al. (2004)
GISSI-Prevenzione Investigators (1999)
Grundt et al. (2003)
Heart Protection Study Collaborative Group (2002)
Heiss et al. (2003)
Hodgson et al. (2005)
Johansen et al. (1999)
Kalin et al. (2002)
Karatzi et al. (2004)
Karatzi et al. (2005)
Kothny et al. (1998)
Liem et al. (2003)
Lonn et al. (2005)
Mukamal et al. (2001)
Mukamal et al. (2002)
Mukamal et al. (2005)
Muntwyler et al. (1998)
Rapola et al. (1997)
Sacks et al. (1995)
Seierstad et al. (2005)
Seljeflot et al. (1999)
Shaper & Wannamethee (2000)
Stein et al. (1999)
Stephens et al. (1996)
Thies et al. (2003)
Thun et al. (1997)
Toole et al. (2004)
von Schacky et al. (1999)
Waters et al. (2002)
Whelan et al. (2004)
Widlansky et al. (2005)
Williams et al. (2004)
* Includes six additional studies.
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confounded by socio-economic status; for exampleNielsen et al.
(2004) have suggested that the relationship between wine intake
and mortality is confounded by the fact that wine is predomi-
nantly consumed in groups of higher socio-economic status.
Thus some or all of the apparent protective effects of moderate
alcohol consumptionmay be due to residual or unmeasured con-
founding, and definitive RCT are required to confirm the effects
on clinical endpoints in CHD patients.
Supplementation with n-3 fish oils has gained substantial
interest, and the American Heart Association recommends
that patients with documented CHD should consume up to
1 g n-3 fish oil per d (Kris-Etherton et al. 2002). These
recommendations have largely evolved from several large-
scale RCT that demonstrate treatment with n-3 fish oils fol-
lowing AMI is associated with a reduction in all-cause and
cardiovascular death (Burr et al. 1989; GISSI-Prevenzione
investigators, 1999). Furthermore, in a recent meta-analysis
of eleven RCT in CHD patients, intake of n-3 fatty acids
was shown to significantly reduce overall mortality, mortality
due to myocardial infarction, and sudden death (Bucher et al.
2002). (In that meta-analysis, work by Singh and colleagues in
relation to n-3 fish oils was excluded (see White, 2005).)
Several studies have also examined the efficacy of the Med-
iterranean diet in the secondary prevention of CHD. For
example, in the Lyon Diet Heart study, de Lorgeril et al.
(1999) demonstrated that a Mediterranean diet substantially
reduced the recurrence of CHD events for up to 4 years
after AMI compared with a low-fat-diet, which was indepen-
dent of traditional risk factors such as high cholesterol and
hypertension. Similarly, in the GISSI-Prevenzione study,
patients who successfully adopted the Mediterranean diet
after AMI demonstrated lower risk of all-cause mortality
over a 6·5-year follow-up period (Barzi et al. 2003). These
findings strongly support the efficacy of the Mediterranean
diet as a secondary prevention care strategy, although it is dif-
ficult to determine which individual components of the diet
account for these effects. Paradoxically, it has been suggested
that a high intake of the 18-carbon a-linolenic acid, a key
component of the Mediterranean diet, is often accompanied
by increases in haemostatic markers that are risk factors for
CHD (Miller, 2005). However, these haemostatic risk factors
may be of little consequence if the arterial wall is healthy
and in combination with a high intake of phytochemicals
and antioxidants provided by the diet.
One of the Bradford Hill criteria for accepting an associ-
ation between exposure and disease outcome as causal is the
existence of a biological mechanism (Hill, 1965). Some of
the proposed mechanisms by which these specific nutrients
may confer benefits for disease management include attenu-
ation of inflammatory processes, reducing thrombosis, and
improving endothelial function. These mechanisms have
been specifically investigated using short-term intervention
studies that will now be reviewed.
Mechanisms of action
Vascular function, haemostasis and inflammation
Atherosclerosis, which is the disorder underlying CHD, is lar-
gely viewed as an inflammatory process in which leucocytes
interact with structurally intact but dysfunctional endothelium
of the arteries (Ross, 1999; Libby, 2002). Inflammatory mar-
kers such as C-reactive protein (CRP) and IL-6 may directly
influence plaque vulnerability and rupture (Blake & Ridker,
2001). The vascular endothelium also plays a key role because
endothelium-derived NO has important vasodilator, anti-
inflammatory, anti-thrombotic and growth-suppressing proper-
ties that are relevant to all stages of atherosclerosis (Vita &
Keaney, 2002). Soluble forms of cellular adhesion molecules,
such as intercellular adhesion molecule-1 (sICAM-1) and vas-
cular cell adhesion molecule-1 (sVCAM-1), are considered to
be markers of endothelial activation (Frijns et al. 1997) and
are elevated in patients suffering from CHD and AMI, and
also appear to be a prognostic factor in AMI (Zeitler et al.
1997). Recent research has focused on these mechanisms in
relation to the efficacy of specific nutrients for the secondary
prevention of CHD (see Fig. 1).
Fig. 1. Proposed mechanisms of specific nutrients in relation to the progression of atherosclerosis. Platelet activation results in platelet surface expression of the
adhesion molecule P-selectin which binds to the leucocyte receptor, P-selectin glycoprotein ligand-1 (PSGL-1), leading to the formation of platelet–leucocyte
aggregates. These interactions result in the release of a number of adhesive and pro-inflammatory molecules which stimulate a variety of processes promoting
long-term CHD. Specific nutrients may potentially intervene with some of these processes.
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Flavonoid-rich dietary components
A substantial number of intervention studies have been con-
ducted to examine the effects of flavonoid-rich beverages on
vascular function, haemostasis, and inflammation in CHD
patients (summarised in Table 2). Improvements in endo-
thelial-dependent dilatation (measured by flow-mediated
dilatation; FMD) have been consistently observed in RCT
after both acute and chronic intake of green and black tea
(Duffy et al. 2001a; Hodgson et al. 2005; Widlansky et al.
2005). These findings are corroborated by recent in vitro
work using endothelial cells that has demonstrated the poly-
phenolic fractions found in green and black tea acutely
enhance NO bioavailability (Anter et al. 2004; Lorenz
et al. 2004). The mechanism may be linked with the antiox-
idant effects of these polyphenolic fractions because it has
been demonstrated that NO activity may be impaired by
free radical production, but is improved during infusion of
vitamin C (Levine et al. 1996; Solzbach et al. 1997;
Taddei et al. 1998; Lembo et al. 2000). However, there
are often no improvements in antioxidant status after tea
intake, which therefore does not support an antioxidant
mechanism. Furthermore, Widlansky et al. (2005) recently
showed that the improvement in endothelial function follow-
ing a 4-week tea intervention was not correlated with
changes in catechin level, although baseline endothelial
function was correlated with dietary flavonoid intake. Thus
the authors suggested that the effects may be due to non-
catechin components of tea such as polymeric polyphenols
or other mechanisms such as tea components acting to che-
late transition metals or alter the absorption of other dietary
components such as oxidised lipids.
Red wine has gained much attention in relation to its
cardioprotective effects, although the findings regarding vas-
cular function are somewhat unclear. Recent studies in CHD
patients have shown that acute ingestion of red wine both
improves (Whelan et al. 2004) and has no effects on FMD
(Karatzi et al. 2004). De-alcoholised wine has also been
shown to have beneficial acute effects on FMD, arterial stiff-
ness, and blood pressure in CHD patients, suggesting that the
effects are due to the constituents of the wine and not the alco-
hol (Karatzi et al. 2004, 2005), although this remains a conten-
tious issue in the epidemiological literature (Bobak &
Marmot, 2005). Furthermore, the acute effects of wine inges-
tion on FMD may be confounded by the vasodilatory effects
of alcohol (Agewall et al. 2000), and chronic intervention
studies in CHD patients are therefore required to clarify the
benefits of red wine. Several other studies in CHD patients
using grape juices that have employed chronic intervention
designs (Stein et al. 1999; Chou et al. 2001) have shown
favourable effects on endothelial function, although both
trials were not placebo controlled. There is also evidence
from one study to show that plasma levels of sVCAM-1,
sICAM-1, and P-selectin were reduced in systemic sclerosis
patients after administration of proanthocyanidins (100 g/d
for 1month) derived from grape seeds (Kalin et al. 2002). A
further study in patients with at least one CVD risk factor,
including history of CHD, hypertension, or hyperlipidaemia,
demonstrated increased plasma NO bioactivity and improved
FMD following a single dose of a cocoa drink rich in
flavan-3-ols (Heiss et al. 2003).
In contrast to the effects on endothelial function there is no
evidence from studies in CHD patients to support an effect of
tea intake on inflammation (Widlansky et al. 2005) or platelet
aggregation (Duffy et al. 2001b). Similarly, there do not
appear to be any effects of red wine on inflammatory markers
or fibrinogen in CHD patients after acute intake (Karatzi et al.
2004; Williams et al. 2004). One possible reason for null find-
ings in relation to procoagulant activity may relate to meth-
odological issues. For example, previous measures of
platelet activation have involved using the platelet aggreg-
ometer device, and plasma concentrations of various platelet
secretory products such as soluble P-selectin and b-thrombo-
globulin. However, these techniques involve a relatively
large amount of sample manipulation before analysis and dis-
play large variability among individuals, which limits their
utility. More recent methods using flow cytometry are thought
to provide a more accurate assessment of platelet activity
(Michelson et al. 2001) and future studies using this method
may therefore produce more reliable results.
n-3 Fish oils
A number of larger studies with longer intervention periods
have examined the effects of n-3 fish oils on progression of
atherosclerosis, vascular function and inflammation, and ather-
osclerotic plaque stability. Fish oil supplementation for 2 years
in an RCT had no effect on the progression of atherosclerosis,
as assessed by changes in carotid artery wall thickness using
ultrasound (Angerer et al. 2002) and was both effective (von
Schacky et al. 1999) and ineffective (Sacks et al. 1995) in
reducing progression using angiography to measure coronary
lumen narrowing. Also, in a prospective cohort study, con-
sumption of at least two servings of fish per week compared
with lower intakes was associated with reduced progression
of atherosclerosis at 3 years follow-up, as assessed by angio-
graphy, in postmenopausal women with CHD and diabetes
(Erkkila et al. 2004). In addition, the effects of fish oil on
the prevention of post-angioplasty restenosis appear to be
equally unclear (for a review, see de Lorgeril & Salen,
2003). However, given that these measures provide little infor-
mation about plaque inflammation or risk of plaque rupture
(Hong et al. 1994; Davies et al. 2004), they do not directly
measure atherosclerosis and are therefore not definitive
studies.
Baumann et al. (1999) have demonstrated reductions in
human gene expression of platelet-derived growth factor and
monocyte chemoattractant protein after 4 weeks of fish oil
supplementation, both of which are important modulators of
the inflammatory response associated with the progression of
atherosclerosis. However, the effects of fish oil on other
inflammatory and haemostatic markers is less clear (see
Table 2). In patients recovering from AMI, studies have
shown rather surprising increases or no changes in vascular
inflammatory markers such as E-selectin and sVCAM-1
(Johansen et al. 1999; Grundt et al. 2003) following fish oil
supplementation, although more favourable effects on haemo-
static activity (Johansen et al. 1999), homocysteine, triacylgly-
cerols, and HDL-cholesterol (Grundt et al. 2003). Elderly men
with high risk for CHD that were supplemented with fish oils
for 18 months also demonstrated a positive correlation
between serum non-esterified DHA and sVCAM-1 (Berstad
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M. Hamer and A. Steptoe854
et al. 2003). In clinically stable CHD patients, reductions in
sVCAM-1 and IL-6 were observed (Seierstad et al. 2005),
although no effects on lipopolysaccharide-stimulated mono-
cyte procoagulant activity or IL-6 release (Eritsland et al.
1995). In contrast, Seljeflot et al. (1999) observed beneficial
effects on procoagulant activity but adverse effects on inflam-
matory markers IL-6 and TNF-a after 6 months of supplemen-
tation in CHD patients. Also, short-term fish oil treatment in
clinically stable CHD patients did not appear to promote
favourable changes in endothelial function (Kothny et al.
1998). Interestingly, CRP appears to be consistently unaf-
fected by fish oil supplementation (Grundt et al. 2003; Seier-
stad et al. 2005). Despite robust epidemiological data
demonstrating a consistent relationship between CRP and
CVD risk (Danesh et al. 2004), the mechanisms relating
CRP to incident cardiovascular events are unclear and recent
data from a large population-based sample suggest CRP is a
poor predictor of atherosclerotic burden after adjustment for
traditional risk factors (Khera et al. 2006).
The wide variation in the dosage, EPA:DHA ratios, and
source (diet or supplement) of various fish oil interventions
may be one explanation for the equivocal findings, although
the meta-analysis by Bucher et al. (2002) did not identify
effects of these parameters in relation to clinical outcomes.
Another possible explanation relates to studies on poly-
morphisms of the endothelial NO synthase gene (Leeson
et al. 2002) and the inflammatory cytokine, TNF-a gene
(Grimble et al. 2002), which suggest only certain patients
could benefit from n-3 fatty acid supplementation. An expla-
nation for the negative effects of fish oil supplementation on
vascular function and inflammatory markers may be related
to poor-quality fish oil that contains oxidation by-products
and is therefore likely to cause an increase in peroxidation
that can result in increased expression of adhesion molecules
via a NF-kB pathway (Collins, 1993). However, in a recent
landmark study in the UK, atherosclerotic plaque stability
was shown to be improved after a modest level of n-3
fish oil supplementation (1·4 g/d for a median of 42 (range
7–189) d) in 188 patients awaiting carotid endarterectomy
surgery (Thies et al. 2003). In this study, n-3 PUFA from
fish-oil were observed to be readily incorporated into athero-
sclerotic plaques that significantly reduced macrophage num-
bers within the plaque and thus reducing the vulnerability of
rupturing. Given that vulnerability of the plaque to rupture
is the primary determinant of acute cardiovascular events
(Ross, 1999), this finding may explain the protective effects
of fish oil towards fatal myocardial infarction and may
render the potential vascular inflammatory effects insignifi-
cant. Recent developments in techniques, such as electron-
beam computed tomography that provide direct information
about coronary artery plaque, and therefore give more prog-
nostic information on hard CHD endpoints in comparison
with previous screening methods (Clouse et al. 2006), may
also be utilised in future studies to examine the effects
of fish oils on plaque progression. Indeed, recently elec-
tron-beam computed tomography was used in a study
that showed an inverse relationship, in a dose–response
fashion, between dietary consumption of linolenic acid and
prevalence of calcified atherosclerotic plaque in the coronary
arteries, after adjusting for other risk factors (Djousse et al.
2005).
Vitamins and L-arginine
Last, a number of previously reviewed supplements, which
include vitamins C and E (Hornig, 2002), folic acid (Doshi
et al. 2003; Moat et al. 2004), and L-arginine (Preli et al.
2002), have also demonstrated beneficial effects on various
markers of vascular function in CHD patients. Nevertheless,
evidence from RCT with clinical endpoints is equivocal. For
example, recent prospective data from the Heart Outcomes
Prevention Evaluation (HOPE) trial demonstrated that
7 years’ supplementation with vitamin E (a-tocopherol;
400 IU/d) in patients with vascular disease or diabetes mellitus
was not efficacious for the prevention of major cardiovascular
events and was actually connected with a higher risk of heart
failure (HOPE Trial Investigators; Lonn et al. 2005). Similar
large-scale RCT in CHD patients have demonstrated benefits
of vitamin E for reducing cardiovascular events (Stephens
et al. 1996; Rapola et al. 1997), although others have not
(GISSI-Prevenzione Investigators, 1999). Also, studies using
a mixture of antioxidant supplements have shown little benefit
(Heart Protection Study Collaborative Group, 2002; Waters
et al. 2002). Furthermore, recent RCT in CHD and cerebral
infarction patients have shown no effects of B vitamin sup-
plementation on clinical endpoints (Liem et al. 2003; Toole
et al. 2004), despite significant reductions in homocysteine
that has been described as an independent predictor of mor-
tality in CHD patients (Nygard et al. 1997). The growing lit-
erature therefore supports the hypothesis that antioxidants
might be effective only over many years and therefore can
only be successfully utilised for primary prevention (Stein-
berg, 1995). The reasons for the possible negative effects of
vitamin supplementation may be linked with the supra-physio-
logical dosages used in some trials that may exert harmful,
pro-oxidant effects.
Mediating factors
Various parameters including lifestyle, health behaviours,
psychological stressors, genetics, and existing risk factors
may interact to determine prognosis in CHD patients. Thus,
the existence of factors such as hypertension, hyperlipidaemia,
obesity, smoking, medication, sedentary lifestyle, and
depression may explain the variation in the efficacy of certain
nutrients in CHD patients. For example, psychosocial factors
are potent pathways for CHD development (Rozanski et al.
2005) and are also linked with an increased risk of mortality
in men with CHD (Barth et al. 2004). Interestingly, in a
case–control study Frasure-Smith et al. (2004) showed that
depressed patients recovering from acute coronary syndromes
had significantly lower serum concentrations of total n-3 and
DHA, and higher arachidonic acid:DHA, arachidonic acid:
EPA, and n-3:n-6 ratios than controls. Therefore the intriguing
association between n-3 fish oils, depression, and cardiovascu-
lar mortality risk in CHD patients should receive more atten-
tion in order to resolve the causal pathways. Given that mental
stress and emotional factors are known to act as acute triggers
for coronary events (Strike & Steptoe, 2005) and CHD
patients demonstrate mental stress-induced ischaemia (Strike
& Steptoe, 2003), and heightened platelet activation and hae-
modynamic reactivity (Strike et al. 2004), specific nutrients
that lower stress responsiveness may be particularly beneficial.
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Although previous studies in healthy participants have indi-
cated that certain nutrients, including vitamin C, n-3 fish
oils, and a-lactalbumin may be effective in reducing psycho-
biological stress responses (Hamer et al. 2005), future studies
in CHD patients are required.
Conclusion
There appear to be a number of specific nutrients that may be
efficacious in the management of CHD (summarised in
Table 3). Interventions that have used n-3 fish oils and Medi-
terranean-style diets have demonstrated beneficial effects on
clinical endpoints, although at present the mechanisms are
unclear. The potential mechanisms conferring benefits of n-3
oils include stabilisation of vulnerable atherosclerotic plaques,
although the effects on haemostatic activity and vascular
inflammation remain equivocal. Extensive clinical endpoint
data in patients for the efficacy of other nutrients are lacking,
although several important findings have been identified that
include the effects of foods high in flavonoid content
(especially tea) on endothelial function in CHD patients.
Based on this evidence, various composite diets, such as the
Mediterranean (Robertson & Smaha, 2001) and the Polymeal
(Franco et al. 2004), could be potentially efficacious as sec-
ondary prevention care strategies for CHD patients.
However, there are a number of issues that should be con-
sidered. First, whether or not CHD patients are willing to
comply with dietary recommendations is debatable. For
example, Burr et al. (2003) demonstrated no benefits of diet-
ary advice (eating more fish, fruits and vegetables) on all-
cause mortality after 3–9 years’ follow-up in elderly men
with angina, which was probably attributable to poor compli-
ance. Second, it is clear that the existence of other lifestyle
and risk factors, genetics, existing medication, and nutritional
status are not always adequately controlled for, which may
explain the variation in the efficacy of certain nutrients.
Last, some of the recent large-scale trials that have shown
adverse effects of vitamin E and n-3 fish oil supplementation
on clinical endpoints suggest that there may be potentially
harmful interactions of some nutrients with specific disease
states. Therefore taken together, there is a need to undertake
more appropriately designed trials in specific clinical popu-
lations, controlling for additional lifestyle and risk factors,
examining potential interactions with medications, and also
establishing methods to increase compliance to dietary
recommendations before specific nutrients can be widely
prescribed for secondary prevention. In addition, future
research should utilise techniques that provide direct measures
of coronary artery plaque in order to perform a valid assess-
ment of how nutritional interventions influence the pro-
gression of atherosclerosis.
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